MM-141

MM-141 is an investigational monoclonal antibody that acts as a tetravalent inhibitor of PI3K/AKT/mTOR, which is a major pro-survival pathway tumor cells use as a resistance mechanism to anti-cancer therapies. Merrimack’s Network Biology approach was used to identify the IGF-1R and ErbB3 receptors and their ligands as key drivers of the PI3K/AKT/mTOR pathway in various cancers. MM-141 is designed to interfere with this pathway by blocking ligand-induced signaling through the IGF-1R and ErbB3 receptors.

Our research suggests that MM-141:
  • Increases the activity of several standard of care therapies in preclinical models, and
  • Could potentially reverse acquired PI3K/AKT/mTOR resistance to chemotherapies and targeted anti-cancer therapies.
MM-141 in the Clinic

Currently Merrimack is conducting a Phase 1 trial evaluating MM-141 at varying dose levels and frequencies. The purpose of this trial is to assess the safety and tolerability of MM-141 as a monotherapy and in combination with everolimus and docetaxel, as well as determine the maximum tolerated dose and identify the recommended Phase 2 dose.

CLICK HERE to learn more about MM-141 in the Clinic. 

Related Content